These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26191250)

  • 1. DNA methylation of hMLH1 correlates with the clinical response to cisplatin after a surgical resection in Non-small cell lung cancer.
    Wu F; Lu M; Qu L; Li DQ; Hu CH
    Int J Clin Exp Pathol; 2015; 8(5):5457-63. PubMed ID: 26191250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Reversal effect of 5-Aza-dc on cisplatin-resistance in human NSCLC cells in vitro].
    Wu F; Hu CH
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):349-53. PubMed ID: 21875463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer.
    Ide T; Kitajima Y; Ohtaka K; Mitsuno M; Nakafusa Y; Miyazaki K
    Oncol Rep; 2008 Jun; 19(6):1571-6. PubMed ID: 18497967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The profile of hMLH1 methylation and microsatellite instability in colorectal and non-small cell lung cancer.
    Okuda T; Kawakami K; Ishiguro K; Oda M; Omura K; Watanabe G
    Int J Mol Med; 2005 Jan; 15(1):85-90. PubMed ID: 15583832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples.
    Wang YC; Lu YP; Tseng RC; Lin RK; Chang JW; Chen JT; Shih CM; Chen CY
    J Clin Invest; 2003 Mar; 111(6):887-95. PubMed ID: 12639995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of heterozygosity combined with promoter hypermethylation, the main mechanism of human MutL Homolog (hMLH1) gene inactivation in non-small cell lung cancer in a Chinese population.
    Geng X; Wang F; Zhang L; Zhang WM
    Tumori; 2009; 95(4):488-94. PubMed ID: 19856662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [RUNX3 promoter hypermethylation and prognosis of early surgically resected non-small cell lung cancers].
    Tang Y; Wu F; Hu C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Jul; 36(7):650-4. PubMed ID: 21873791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
    Meng CF; Dai DQ; Guo KJ
    Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
    Filipits M; Pirker R; Dunant A; Lantuejoul S; Schmid K; Huynh A; Haddad V; André F; Stahel R; Pignon JP; Soria JC; Popper HH; Le Chevalier T; Brambilla E
    J Clin Oncol; 2007 Jul; 25(19):2735-40. PubMed ID: 17602078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer.
    Zhang H; Zhang S; Cui J; Zhang A; Shen L; Yu H
    Aust N Z J Obstet Gynaecol; 2008 Oct; 48(5):505-9. PubMed ID: 19032668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation profiling of archived non-small cell lung cancer: a promising prognostic system.
    Safar AM; Spencer H; Su X; Coffey M; Cooney CA; Ratnasinghe LD; Hutchins LF; Fan CY
    Clin Cancer Res; 2005 Jun; 11(12):4400-5. PubMed ID: 15958624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.
    Buhl IK; Santoni-Rugiu E; Ravn J; Hansen A; Christensen IJ; Jensen T; Pratt B; Askaa J; Jensen PB; Knudsen S; Sørensen JB
    PLoS One; 2018; 13(3):e0194609. PubMed ID: 29566065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
    Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
    Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter methylation of the hMLH1 gene and protein expression of human mutL homolog 1 and human mutS homolog 2 in resected esophageal squamous cell carcinoma.
    Tzao C; Hsu HS; Sun GH; Lai HL; Wang YC; Tung HJ; Yu CP; Cheng YL; Lee SC
    J Thorac Cardiovasc Surg; 2005 Nov; 130(5):1371. PubMed ID: 16256791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FATS expression is associated with cisplatin sensitivity in non small cell lung cancer.
    Tian Y; Zhang J; Yan S; Qiu L; Li Z
    Lung Cancer; 2012 Jun; 76(3):416-22. PubMed ID: 22137560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter hypermethylation of mismatch repair gene hMLH1 predicts the clinical response of malignant astrocytomas to nitrosourea.
    Fukushima T; Katayama Y; Watanabe T; Yoshino A; Ogino A; Ohta T; Komine C
    Clin Cancer Res; 2005 Feb; 11(4):1539-44. PubMed ID: 15746058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High ABCG4 Expression Is Associated with Poor Prognosis in Non-Small-Cell Lung Cancer Patients Treated with Cisplatin-Based Chemotherapy.
    Yang G; Wang XJ; Huang LJ; Zhou YA; Tian F; Zhao JB; Chen P; Liu BY; Wen MM; Li XF; Zhang ZP
    PLoS One; 2015; 10(8):e0135576. PubMed ID: 26270652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer.
    Hsu HS; Wen CK; Tang YA; Lin RK; Li WY; Hsu WH; Wang YC
    Clin Cancer Res; 2005 Aug; 11(15):5410-6. PubMed ID: 16061855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.